Listed by the USPTO as LY, KRISTINA ELISABETH
Tech Center 1600 • Art Units: 1641 1663 1671 1674
This examiner grants 38% of resolved cases
LY, KRISTINA ELISABETH is associated with tech center 1600 and art unit 1641. The profile covers 8 resolved cases, with a 37.5% allowance rate. The median time to allowance is 1087 days. Interviews correspond to a 100.0% lift in the allowance outcome.
The small resolved-case volume limits the breadth of the record, but every available interview-associated observation is reflected in a very large lift measure. Counsel may consider interview practice carefully while relying on application-specific analysis rather than treating the measure as a general prediction. The leading companies are Humabs Biomed SA, Ucl Business Ltd., and The Ohio State University.
The leading firms are Fox Rothschild LLP, MEDLER FERRO WOODHOUSE & MILLS PLLC, and BakerHostetler. They provide the listed representation context.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18558973 | HUMAN ANTI-CORONAVIRUS PEPTIDE VACCINES AND METHODS OF THEIR USE | Non-Final OA | Ohio State Innovation Foundation |
| 18271366 | MONOVALENT AND MULTIVALENT VACCINES FOR PREVENTION AND TREATMENT OF DISEASE | Final Rejection | The Regents of the University of California |
| 18779108 | METHOD AND KIT FOR DETECTING INFLUENZA A AND B VIRUSES | Non-Final OA | DELTA ELECTRONICS, INC. |
| 18286657 | METHOD FOR PRODUCING VIRUS PARTICLES | Non-Final OA | The University of Tokyo |
| 18693225 | Rapid Acting Vaccine Against Nipah Virus | Non-Final OA | Board of Regents, The University of Texas System |
| 18363520 | METHOD FOR SELECTING ANTIGENIC VIRAL SEQUENCES FOR VACCINES AND THERAPEUTICS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18257215 | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins | Non-Final OA | Pfizer Inc. |
| 18264446 | VACCINATION FOR PROTECTING POULTRY AGAINST A POULTRY PATHOGEN | Non-Final OA | Intervet Inc. |
| 18262033 | Therapeutic Viral Vaccine | Non-Final OA | GlaxoSmithKline Biologicals SA |
| 18332805 | COMPOSITIONS, KITS, METHODS FOR DETECTING AND IDENTIFYING PATHOGENS THAT CAUSE RESPIRATORY TRACT INFECTIONS AND USE THEREOF | Non-Final OA | SANSURE BIOTECH INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.5% of resolved applications examined by Kristina Elisabeth Ly were allowed (8 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +100.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kristina Elisabeth Ly took 1,087 days on average from filing to allowance.
Kristina Elisabeth Ly examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
